Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Under Armour Men Heat Gear Performance Tech T-Shirt
Popular Articles
Teeth Whitening Products

MAGI's 2009 Clinical Research Conference - WEST
If you are a clinical research novice or veteran with a study sponsor, research site, or CRO in a corporate, academic or other organization, you will find a comprehensive program that focuses on your current needs and broadens your knowledge. MAGI conferences feature balanced co-presentations from sponsors, sites and CROs, real-life examples, practical tips, and lots of interaction and networking. This year"s conference will feature:
generic viagra online
Analyses: CBO Director Elmendorf Becomes Center Of Attention
Several analyses today on the Congressional Budget Office, and its director, Douglas Elmendorf, who has been at the center of increasing debate over health care reform after the recent release of the CBO"s "score" of health system overhaul legislation. President Barack Obama met with him Monday in a move that has spurred Republican criticism.
News of the day
Smoke Alarm Launches New Cannabis And Tobacco Education Initiative
Smoke Alarm, a new not for profit Community Interest Company, is launching a series of nationwide seminars to help Smoking Cessation Therapists understand more about the addictive interdependency of cannabis and tobacco.
Public Health

Oral Rivaroxaban As Prevention For Symptomatic Venous Thromboembolism

In this study data from three studies comparing the new oral anticoagulant rivaroxaban against enoxaparin injected subcutaneously was assessed and conclusions drawn about effectiveness of both types of treatment. Rivaroxaban was started six to eight hours after surgery, whereas enoxaparin was injected the previous evening and then at six to eight hours following wound closure. Thereafter, both were administered every 24 hours in a double-dummy fashion: all patients received either placebo injections or placebo tablets. The results showed that of 9581 patients in the study across 487 centres in 38 countries rivaroxaban significantly reduced the incidence of symptomatic venous thromoembolism compared with enoxaparin (0.4% and 0.8% respectively) without an increase in the risk of major bleeding in patients undergoing elective hip and knee replacement surgery. Read the full text article. The Journal of Bone and Joint Surgery


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009